Followers | 376 |
Posts | 17197 |
Boards Moderated | 3 |
Alias Born | 03/07/2014 |
![](https://investorshub.advfn.com/uicon/458287.png?cb=1657037051)
Monday, May 05, 2014 10:31:49 AM
Aren't they both referring to the 5-person, Angel trial in Mexico, the only phase I, Mexico based, "Adipose" trial or "study" that I've ever heard of them doing? Why would two PR's, a week or two apart, be giving different (IMO), numbers as the "results" -when referring to the same "trial" or study (whatever one wants to call it- I'm assuming it's the ANGEL, phase I??)
What's up with that?
PR dated April 30th, 2014:
" Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, presented at the 16th Clinical Applications for Age Management Medicine Group conference and Scientific Seminar in Orlando, Florida April 24-27.
Kristin Comella, Bioheart's Chief Scientific Officer, presented for the first time the Angel 6 month trial data to hundreds of physicians and health care professionals. At the 6 month time point, patients are demonstrating an average improvement in exercise capacity or a six minute walk test of approximately 68 meters (p=.07) as compared to an average improvement of 47 meters at 3 months (p=0.12). Eighty percent of the patients showed an improvement in their exercise capacity from 3 months to 6 months post stem cell injection.
Another end point in the study is ejection fraction (EF) by echocardiogram. At the 3 month time point, 100% of the patients demonstrated either improvement or stayed the same. After 3 months, patients showed an average absolute improvement of 3 percentage points in ejection fraction (p=0.17). The patients continued to improve from 3 months to 6 months with a statistically significant average absolute improvement of 10 percentage points (p=0.01)."
PR dated today- in what appears to also be a rehash, summary IMO, of what must be the ANGEL, 5-person, "ANGEL" trial in Mexico:
" Tijuana, Mexico, five congestive heart failure patients were successfully treated in the initial pilot trial at Hospital Angeles Tijuana. Patients underwent a mini-lipoaspiration procedure where 60ccs of fat were removed. This fat was processed to obtain the stromal vascular fraction (SVF) which contains mesenchymal stem cells, progenitor/endothelial cells, pericytes, hematopoetic stem cells and more. The SVF was injected into the damaged areas of the heart using Bioheart's MyoCath® catheter allowing for a minimally invasive delivery. Patients were followed on protocol for 6 months and demonstrated on average, an absolute improvement of 13 percentage points in ejection fraction and an increase of 100 meters in their 6 minute walk distance."
Doesn't make any sense to me, IMO. What am I missing here- it's two "result" descriptions that don't even match IMO (68 meters versus 100 meters? and 10 percent versus 13 percent? Did the "data" just change in a few days or what?)? Confusing IMO? The two "PR's" as far as I can tell- must be referring to the same, "ANGEL" trial in Mexico, no?
There are not, two different, 5-person "studies/trials" in Mexico that I'm aware of, unless I'm missing something here?
FEATURED Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • Sep 10, 2024 11:00 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM